title: Anti-angiogenic effect of bortezomib in patients with multiple myeloma.
authors.affiliation: Department of Haematology, Faculty of Medicine Imperial College London, Hammersmith Hospital, London, UK.
authors.forename: Marianna
authors.initials: M
authors.lastname: Politou
authors.forename: Kikkeri
authors.initials: K
authors.lastname: Naresh
authors.forename: Evangelos
authors.initials: E
authors.lastname: Terpos
authors.forename: Danielle
authors.initials: D
authors.lastname: Crawley
authors.forename: Irvin
authors.initials: I
authors.lastname: Lampert
authors.forename: Jane F
authors.initials: JF
authors.lastname: Apperley
authors.forename: Amin
authors.initials: A
authors.lastname: Rahemtulla
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001897:Boronic Acids / Q000627:therapeutic use*; D000069286:Bortezomib; D005260:Female; D006801:Humans; D008297:Male; D008833:Microcirculation / Q000187:drug effects / Q000473:pathology; D008875:Middle Aged; D009101:Multiple Myeloma / Q000098:blood supply* / Q000188:drug therapy* / Q000378:metabolism; D009389:Neovascularization, Pathologic / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D011480:Protease Inhibitors / Q000627:therapeutic use; D011719:Pyrazines / Q000627:therapeutic use*; D012259:Ribonuclease, Pancreatic / Q000378:metabolism; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; D001897:Boronic Acids; D011480:Protease Inhibitors; D011719:Pyrazines; D042461:Vascular Endothelial Growth Factor A; D000069286:Bortezomib; C046366:angiogenin; D012259:Ribonuclease, Pancreatic